APLS — Apellis Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $3.96bn
- $4.06bn
- $396.59m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 352 | 878 | 701 | 552 | 351 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | 10.1 | 29.2 | 224 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 373 | 917 | 824 | 720 | 766 |
Net Property, Plant And Equipment | 15.8 | 24.5 | 26.1 | 24.9 | 21.1 |
Other Long Term Assets | |||||
Total Assets | 389 | 961 | 882 | 760 | 789 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 65.8 | 128 | 132 | 168 | 248 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 355 | 756 | 683 | 590 | 594 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 34.2 | 205 | 199 | 170 | 195 |
Total Liabilities & Shareholders' Equity | 389 | 961 | 882 | 760 | 789 |
Total Common Shares Outstanding |